Analysis of boron neutron capture reaction sensitivity using Monte Carlo simulation and proposal of a new dosimetry index in boron neutron capture therapy

1. Suzuki M. Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era. IntJ Clin Oncol 2020;25:43–50.

2. Morris GM, Coderre JA, Hopewell JW et al. Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. Radiother Oncol 1994;32:144–53.

3. Coderre JA, Makar MS, Micca PL et al. Derivations of relative biological effectiveness for the high-let radiations produced during boron neutron capture irradiations of the 9l rat gliosarcoma in vitro and in vivo. IntJ Radiat Oncol Biol Phys 1993;27:1121–9.

4. Sato T, Masunaga SI, Kumada H et al. Microdosimetric Modeling of biological effectiveness for boron neutron capture therapy con- sidering intra- and intercellular heterogeneity in 10B distribution. Sci Rep 2018;8:988.

5. Ono K, Tanaka H, Suzuki M. Reevaluation of CBE value of BPA for hepatocytes. Appl Radiat Isot 2020;161:109159.

6. Gonzalez SJ, Cruz GAS. The photon-isoeffective dose in boron neutron capture therapy. Radiat Res 2012;178:609–21.

7. Aihara T, Hiratsuka J. Evaluation of Fluoride-18-Labeled Boronophenylalanine-positron emission tomography imaging for the assessment of boron neutron capture therapy in patients with recurrent head and neck squamous cell carcinoma. Otolaryngology 2016;6:277. https://doi.org/10.4172/2161-119x.1000277.

8. Ono K, Tanaka H, Tamari Y et al. Proposal for determining abso- lute biological effectiveness of boron neutron capture therapy - the effect of 10B(n,α)7Li dose can be predicted from the nucleocyto- plasmic ratio or the cell size. J Radiat Res 2019;60:29–36.

9. Aihara T, Hiratsuka J, Kamitani N et al. Boron neutron cap- ture therapy for head and neck cancer: relevance of nuclear- cytoplasmic volume ratio and anti-tumor effect. -a preliminary report. Appl Radiat Isot 2020;163:109212.

10. Yoshida F, Matsumura A, Shibata Y et al. Cell cycle dependence of boron uptake from two boron compounds used for clinical neutron capture therapy. Cancer Lett 2002;187:135–41.

11. Cooper GM. The Cell: AMolecular Approach, 2nd edn. Sunderland (MA): Sinauer Associates, 2000.

12. Takeno S, Tanaka H, Watanabe T et al. Quantitative autoradiog- raphy in boron neutron capture therapy considering the particle ranges in the samples. Phys Med 2021;82: 306–20.

13. Van Vliet-Vroegindewej C, Wheeler F, Stecher-Rasmussen F et al. Microdosimetry model for boron neutron capture therapy: II. Theoretical estimation of the effectiveness function and surviving fractions. Radiat Res 2001;155:498–502.

14. Jul N, Gabel D, Foster S et al. The Monte Carlo simulation of the biological effect of the 10B(n, alpha)7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiat Res 1987;111:14–25.

15. Ono K, Masunaga SI, Kinashi Y et al. Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys 1996;34:1081–6.

16. Wongthai P, Hagiwara K, Miyoshi Y et al. Boronophenylala- nine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci 2015; 106:279–86.

17. Chandra S, Lorey DR, Smith DR. Quantitative subcellular sec- ondary ion mass spectrometry (SIMS) imaging of boron-10 and boron-11 isotopes in the same cell delivered by two combined BNCT drugs: in vitro studies on human glioblastoma T98G cells. Radiat Res 2002;157:700–10.

18. Hattori Y, Ishimura M, Ohta Y et al. Detection of boronic acid derivatives in cells using a fluorescent sensor. Org Biomol Chem 2015;13:6927–30.

19. Wada Y, Hirose K, Harada T et al. Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy. J Radiat Res 2018;59:122–8.

20. Lu X. The role of large neutral amino acid transporter (LAT1) in cancer. Curr Cancer Drug Targets 2019;19:863–76.

21. Taylor PM. Role of amino acid transporters in amino acid sens- ing. AmJ Clin Nutr 2014;1:223S–30S. https://doi.org/10.3945/a jcn.113.070086.

22. Zhou H, Hong M, Chai Y et al. Consequences of cytoplas- mic irradiation: studies from microbeam. J Radiat Res 2009;50: 1–10.

23. Sato K, Imai T, Okayasu R et al. Heterochromatin domain number correlates with X-ray and carbon-ion radiation resistance in cancer cells. Radiat Res 2014;182:408–19.

24. Caswell RS, Coyne JJ, Randolph ML. Kerma factors for neutron energies below 30 MeV. Radiat Res 1980;83:217–54.